Subcutaneous · Amylin analog
KBP-042
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
0
Recruiting
0
Completed
1
Sites
29
Countries
6
Endpoints
6
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
4
Weight & body composition
1
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03230786Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes | KBP-042 Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 30 | Jul 2018 | — |